Kvistgaard, Denmark – Bavarian Nordic A/S, a biotechnology company, announced that Paul Chaplin has been appointed new president and CEO of the company.[break]
Prior to joining Bavarian Nordic in 1999, Dr. Chaplin worked in vaccine research with the Institute for Animal Health in UK and CSIRO, the Cooperative Research Centre for Vaccine Technology in Australia. In 2000, he was appointed head of research and in 2004 he was appointed Executive Vice President.
Amongst others things, he has led the development program for the IMVAMUNE smallpox vaccine as well as been responsible for the successful collaboration on this and other vaccines with the U.S. Government throughout the years. Since 2010 he has held the position as Division President, Infectious Diseases.
Dr. Chaplin holds a Ph.D. in Immunology from Bristol University. He replaces Anders Hedegaard who has served in this position since 2007. Mr. Hedegaard leaves the Company to join GN ReSound A/S as CEO.
As part of the management changes, Executive Vice President and CFO Ole Larsen will become register - May 29, 2014, Kvistgaard, Denmark – Bavarian Nordic A/S, a biotechnology company, announced that Paul Chaplin has been appointed new president and CEO of the company.
Article continues below
Prior to joining Bavarian Nordic in 1999, Dr. Chaplin worked in vaccine research with the Institute for Animal Health in UK and CSIRO, the Cooperative Research Centre for Vaccine Technology in Australia. In 2000, he was appointed head of research and in 2004 he was appointed Executive Vice President.
Amongst others things, he has led the development program for the IMVAMUNE smallpox vaccine as well as been responsible for the successful collaboration on this and other vaccines with the U.S. Government throughout the years. Since 2010 he has held the position as Division President, Infectious Diseases.
Dr. Chaplin holds a Ph.D. in Immunology from Bristol University. He replaces Anders Hedegaard who has served in this position since 2007. Mr. Hedegaard leaves the Company to join GN ReSound A/S as CEO. ■
LATEST MOVES FROM Kvistgaard, Denmark – Bavarian Nordic A/S, a biotechnology company, announced that Paul Chaplin has been appointed new president and CEO of the company.[break]
Prior to joining Bavarian Nordic in 1999, Dr. Chaplin worked in vaccine research with the Institute for Animal Health in UK and CSIRO, the Cooperative Research Cen